TGFB1 and neoplasm: Given that a 100 nm size is more representative of currently approved nanomedicines (e.g., Abraxane) for cancer treatment, size in clinical trial, we next investigated whether combined DC101 and anti‐TGFβ1 antibody treatment enhance the distribution and penetration of 100 nm PEGylated polystyrene (PS) nanoparticles within the tumor.